aVaxziPen management team is made up of industry professionals with several decades of wide-ranging experience in the vaccine industry.
Chief Business Officer and Director
Robin has over 25 years of experience in the pharmaceutical industry with a strong executive level commercial and business development focus. Robin is a highly experienced senior level leader with a strong track record in biotech fund raising, commercializing products from pre-clinical through to post license as well as building commercial teams and leading them to exceed their strategic and commercial goals in both Global Pharmaceutical and Biotech organizations.
Prior to joining aVaxziPen, Robin worked in a variety of senior level commercial roles at Janssen Cilag (Johnson & Johnson) where he was a key part in a number of ground-breaking therapeutic product launches across a range of the therapeutic areas from Oncology to Infectious diseases with a focus on HIV, Hepatitis and the wider Infectious disease portfolio. Robin worked as part of the EMEA strategic marketing group in the EMEA and Global business development teams where he focused on licensing and acquisition and was involved in a number of high-profile asset acquisitions into the organization.
In 2021 Robin moved into the Biotech space, joining Emergex Vaccines with responsibility for the commercial strategy for the organization as well supporting fund raising activities. Robin joined aVaxziPen in February 2023 where he works as Chief Business Officer, leading all aspects of commercial development and partnering for the organization.
COO/CFO and Director
Liz joined aVaxziPen in August 2021 and has over 20 years pharmaceutical industry experience, a strong background in clinical development and a proven track record of driving results focussed operational excellence.
Prior to joining Enesi, Liz was Senior Director and Head of Clinical Operations, Vaccitech (UK), a vaccine company spun out from Oxford University. She worked alongside the senior leadership to set strategy while building high functioning teams and successfully leading all programmes into early stage, clinical studies, during a high value funding round and IPO.
Before Vaccitech, she was Project Director and Director of Patient Engagement at Covance, a leading international contract research organisation, building collaborative networks of patient advocates, and financially managing clinical programmes with high value large pharmaceutical clients.
Liz also led a number of clinical programmes at Vectura (UK), a leading inhaled product development company leveraging proprietary device and formulation technologies, during a period of acquisition and growth, creating and implementing vendor procurement and management processes, and successfully completing first in human clinical studies.
Liz holds a BSc (Hons) in biology with analytical chemistry, and a Master’s Degree in Business Administration from the University of Liverpool (UK).
Dr Keith Howard
Keith brings more than 35 years of experience in vaccine development spent in industry and academia and has led the development of viral vectors and vaccines across multiple formats (recombinant, viral vector, live attenuated virus) at several biotechnology and pharmaceutical companies.
Prior to joining aVaxziPen, Keith was Chief Development Officer at Oxford-based Vaccitech, where he was the head of R&D, process development and manufacturing for its novel viral vector vaccine programmes. Before that, he was Senior Director and Head of Manufacturing Science & Technology for FluMist (live attenuated influenza vaccine) at Medimmune.
Before this, Keith was a Director of Vaccines Analytical Development at Pfizer Biotech, and he also spent ten years at Baxter AG in various positions including that of Director of Vaccines R&D. Further roles included Head of Vector Development at Oxxon Therapeutics and Director of Neuronal Gene Therapy at Cantab Pharmaceuticals.
Keith spent 13 years in academia studying infectious diseases, virology and immunology at University College London and the London School of Hygiene and Tropical Medicine. He received a BSc in Biological Sciences from the University of Leicester and a PhD in Molecular Parasitology from the University of London.
Head of R&D
Chris has worked in novel pharmaceutical delivery technology development for more than 12 years and has a strong background in process development and pharmaceutical engineering.
Prior to his appointment as Head of Research and Development at aVaxziPen Chris worked as a Manufacturing Engineer and subsequently Head of Manufacturing at a predecessor company to aVaxziPen. He has led the development of manufacturing processes from laboratory bench to GMP-scale operation. In 2016 he oversaw a successful phase I clinical trial delivered using an earlier version of the aVaxziPen injector system technology.
In his current role Chris manages the R&D team within aVaxziPen and supports technical, Business Development and strategic activities within the company.
Chris holds a BA and MEng in Engineering from the University of Cambridge (UK).
Director of Quality, Regulatory and Compliance
Karen has extensive experience in the pharmaceutical industry gained in the development, manufacture and regulatory assurance of vaccines, biologics, active pharmaceutical ingredients and medicinal drug products.
She has worked in Europe and USA and well as UK and has led projects to prepare companies for their first global new drug registration and associated inspections from the regulatory authorities, including MHRA, EMA, FDA and ANVISA.
Prior to furthering her career in Regulatory and Quality, Karen worked in R & D and Operations. She has supported the conduct of safety and clinical efficacy studies around the world and has championed the introduction of new and improved quality systems to support Good Clinical, Manufacturing, Laboratory and Distribution Practices. As a member of the core team, she has been involved in new build, construction and remediation of pharmaceutical facilities for active ingredients, sterile and high risk medicinal products and has led the associated qualification and validation effort.
Karen’s experience has been gained in GSK, MSD, Chiroscience, Celltech, NextPharma Technologies, GW Pharmaceuticals, Sandoz and Vaccine Manufacturing and Innovation Centre. She is the Chair of Research Ethics at Cranfield University and is a Public Partner for National institute for Health and Care Research in conjunction with Imperial College, London.
Executive Assistant & Company Secretary
Carol has over 20 years’ Biotech and Life Sciences experience working alongside C-Suite Executives and more than 10 years in a Company Secretary role.
Prior to joining aVaxziPen, Carol supported senior leadership at Oxford Diffraction, to sell Diffraction systems to Universities and Commercial Clients. She was an integral part of the Team that implemented a successful sale of the Company, in 2008, to Varian Inc and later Agilent Technologies.
Carol worked as the Harwell Centre Business Manager at Synexus, a phase II-IV clinical trials patient recruitment company spun out of AEA Technology and the Edgebright Partnership. She was responsible for building relationships with General Practitioners, Pharmaceutical Companies, Clinical Research Organisation, Hospital Consultants and Ethics Committees to successfully identify patients for clinical trials in women’s healthcare, osteoporosis, arthritis, IBS and migraine. She also led a team of Medical Practitioners, Nurses, Radiographers and Administrators who implemented the clinical studies.
Carol holds a Professional Certificate in Management from the Open University, UK.